Federal Register / Vol. 85, No. 229 / Friday, November 27, 2020 / Notices 76087 

through the advice and counsel of this 

group. 

Inquiries may be directed to Claire 

Harris, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail Stop Code 4875), Telephone (301) 

496–2123, or harriscl@mail.nih.gov. 

Dated: November 20, 2020. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–26167 Filed 11–25–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Vaccine Research Center 

Board of Scientific Counselors, NIAID. 

The meeting will be closed to the public 

as indicated below in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended for the review, discussion, 

and evaluation of individual grant 

applications conducted by the 

NATIONAL INSTITUTE OF ALLERGY 

AND INFECTIOUS DISEASES, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Vaccine Research 

Center Board of Scientific Counselors, NIAID. 

Date: December 15–16, 2020. 

Time: 8:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 40 Convent Drive, Bethesda, MD 

20892, (Virtual Meeting). 

Contact Person: John R. Mascola, MD, 

Director, Vaccine Research Center, National 

Institute of Allergy and Infectious Diseases, 

National Institutes of Health, 40 Convent 

Drive, Bethesda, MD 20892, (301) 496–1852, 

jmascola@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 20, 2020. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–26150 Filed 11–25–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Initial Review Group; Behavior and 

Social Science of Aging Review Committee 

NIA–S. 

Date: February 4–5, 2021. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Carmen Moten, Ph.D., 

MPH, Scientific Review Officer, Scientific 

Review Branch, National Institute on Aging, 

National Institutes of Health, Gateway Bldg., 

2C212, 7201 Wisconsin Avenue, Bethesda, 

MD 20814, (301) 402–7703, cmoten@

mail.nih.gov. 

Name of Committee: National Institute on 

Aging Initial Review Group; Biological Aging 

Review Committee NIA–B. 

Date: February 11–12, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Bita Nakhai, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, National 

Institutes of Health, Gateway Bldg., 2C212, 

7201 Wisconsin Avenue, Bethesda, MD 

20892, (301) 402–7701, nakhaib@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: November 24, 2020. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–26369 Filed 11–25–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information may be obtained 

by communicating with Betty B. Tong, 

Ph.D., National Institute of Diabetes and 

Digestive and Kidney Diseases, 

Technology Advancement Office, 12A 

South Drive Suite 3011, Bethesda, MD 

20892; telephone: 301–451–7836; email: 

tongb@mail.nih.gov. A signed 

Confidential Disclosure Agreement may 

be required to receive any unpublished 

information. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Triazole Derivatives as P2Y14 Receptor 

Antagonists 

The technology describes the 

composition of small molecule 

compounds that are antagonists of the 

P2Y14 receptor. Also provided are 

methods of using the compounds, 

including a method of treating a 

disorder, such as inflammation, 

diabetes, insulin resistance, 

hyperglycemia, a lipid disorder, obesity, 

a condition associated with metabolic 

syndrome, and asthma, and a method of 

antagonizing P2Y14 receptor activity in 

a cell. This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404. 

Potential Commercial Applications: 

Development of P2Y14 receptor 

antagonist for treatment of disorders, 

such as: 

• Inflammation 

• diabetes 

• obesity 

• asthma 


jbell on DSKJLSW7X2PROD with NOTICES